PMID- 27843314
OWN - NLM
STAT- MEDLINE
DCOM- 20170207
LR  - 20181202
IS  - 1178-2013 (Electronic)
IS  - 1176-9114 (Print)
IS  - 1176-9114 (Linking)
VI  - 11
DP  - 2016
TI  - Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) 
      nanoparticles for dendritic cell-based cancer immunotherapy.
PG  - 5729-5742
AB  - Dendritic cells (DCs) are potent professional antigen-presenting cells that are 
      capable of initiating a primary immune response and activating T cells, and they 
      play a pivotal role in the immune responses of the host to cancer. Prior to 
      antigen presentation, efficient antigen and adjuvant uptake by DCs is necessary 
      to induce their maturation and cytokine generation. Nanoparticles (NPs) are 
      capable of intracellular delivery of both antigen and adjuvant to DCs. Here, we 
      developed an advanced poly(d,l-lactide-co-glycolide) (PLGA)-NP encapsulating both 
      ovalbumin (OVA) as a model antigen and polyinosinic-polycytidylic acid sodium 
      salt (Toll-like receptor 3 ligand) as an adjuvant to increase intracellular 
      delivery and promote DC maturation. The PLGA-NPs were taken up by DCs, and their 
      uptake greatly facilitated major histocompatibility class I antigen presentation 
      in vitro. Moreover, vaccination with PLGA-NP-treated DCs led to the generation of 
      ovalbumin-specific CD8(+) T cells, and the resulting antitumor efficacy was 
      significantly increased in EG.7 and TC-1 tumor-bearing mice compared to control 
      mice (P<0.01). Taken together, these findings demonstrated that the PLGA-NP 
      platform may be an effective method for delivering tumor-specific antigens or 
      adjuvants to DCs.
FAU - Han, Hee Dong
AU  - Han HD
AD  - Department of Immunology, School of Medicine, Konkuk University, Chungwondaero, 
      Chungju-Si, Chungcheongbuk-Do.
FAU - Byeon, Yeongseon
AU  - Byeon Y
AD  - Department of Immunology, School of Medicine, Konkuk University, Chungwondaero, 
      Chungju-Si, Chungcheongbuk-Do.
FAU - Kang, Tae Heung
AU  - Kang TH
AD  - Department of Immunology, School of Medicine, Konkuk University, Chungwondaero, 
      Chungju-Si, Chungcheongbuk-Do.
FAU - Jung, In Duk
AU  - Jung ID
AD  - Department of Immunology, School of Medicine, Konkuk University, Chungwondaero, 
      Chungju-Si, Chungcheongbuk-Do.
FAU - Lee, Jeong-Won
AU  - Lee JW
AD  - Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan 
      University School of Medicine, Seoul.
FAU - Shin, Byung Cheol
AU  - Shin BC
AD  - Bio/Drug Discovery Division, Korea Research Institute of Chemical Technology, 
      Yuseong-gu, Daejeon.
FAU - Lee, Young Joo
AU  - Lee YJ
AD  - Department of Bioscience and Biotechnology, Sejong University, Kwang-Jin-Gu, 
      Seoul, South Korea.
FAU - Sood, Anil K
AU  - Sood AK
AD  - Department of Gynecologic Oncology and Reproductive Medicine; Department of 
      Cancer Biology; Center for RNA Interference and Non-coding RNA, The University of 
      Texas MD Anderson Cancer Center, TX, USA.
FAU - Park, Yeong-Min
AU  - Park YM
AD  - Department of Immunology, School of Medicine, Konkuk University, Chungwondaero, 
      Chungju-Si, Chungcheongbuk-Do.
LA  - eng
PT  - Journal Article
DEP - 20161102
PL  - New Zealand
TA  - Int J Nanomedicine
JT  - International journal of nanomedicine
JID - 101263847
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Toll-Like Receptor 3)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Animals
MH  - Antigen Presentation/immunology
MH  - Antigens, Neoplasm/immunology
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - *Immunotherapy
MH  - Lactic Acid/*chemistry
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Nanoparticles/*chemistry
MH  - Neoplasms, Experimental/immunology/pathology/*therapy
MH  - Ovalbumin/immunology
MH  - Polyglycolic Acid/*chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - T-Lymphocytes/immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Thymoma/immunology/pathology/*therapy
MH  - Thymus Neoplasms/immunology/pathology/therapy
MH  - Toll-Like Receptor 3/*immunology/metabolism
PMC - PMC5098754
OTO - NOTNLM
OT  - PLGA nanoparticles
OT  - antigen delivery
OT  - cancer immunotherapy
COIS- The authors report no conflicts of interest in this work.
EDAT- 2016/11/16 06:00
MHDA- 2017/02/09 06:00
PMCR- 2016/11/02
CRDT- 2016/11/16 06:00
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
PHST- 2016/11/02 00:00 [pmc-release]
AID - ijn-11-5729 [pii]
AID - 10.2147/IJN.S109001 [doi]
PST - epublish
SO  - Int J Nanomedicine. 2016 Nov 2;11:5729-5742. doi: 10.2147/IJN.S109001. 
      eCollection 2016.